Martek Biosciences To Be Acquired By Royal DSM For $31.50/Share Cash (MATK)

by Benzinga Staff
December 21, 2010 7:34 AM | 10 seconds read |
In a deal 35% above Martek Biosciences MATK closing price yesterday, MATK is being acquired by Royal DSM for $31.50/share. The total deal will be worth $1.087 billion.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: NewsM&ABiotechnologyHealth Care
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!